The MONALEESA-3 phase III trial showed that the combination of ribociclib with fulvestrant is equally effective in prolonging PFS (median PFS of 20.5 months for the ribociclib plus fulvestrant arm vs. 12.8 months for the fulvestrant arm) in postmenopausal women with HR+/HER2- advanced breast cancer.661 The most recent update corroborates the significant benefit of ribociclib plus fulvestrant in OS as well.662. Here, ERBB2 is linked to breast cancer.